E09.359 vs H35.3191
E09.359 (Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema) compared with H35.3191 (Nonexudative age-related macular degeneration, unspecified eye, early dry stage), from the official CMS tabular data. Both may be reported when both conditions are documented (Excludes2).
Can these codes be reported together?
Yes, when both are documented. H35.3191 carries an Excludes2 note covering E09.359: “diabetic retinal disorders (E08.311-E08.359, E09.311-E09.359, E10.311-E10.359, E11.311-E11.359, E13.311-E13.359)”
Excludes2 marks distinct conditions — both may be reported when both are documented.
Side by side
| E09.359Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema | H35.3191Nonexudative age-related macular degeneration, unspecified eye, early dry stage | |
|---|---|---|
| Billing status | Non-billable header | Billable |
| Classification | E00-E89 — Endocrine, Nutritional and Metabolic Diseases (E00-E89) | H00-H59 — Diseases of the Eye and Adnexa (H00-H59) |
| Definition | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema is a non-billable ICD-10-CM category code (E09.359). | Nonexudative age-related macular degeneration, unspecified eye, early dry stage is a billable ICD-10-CM diagnosis code (H35.3191). |
| 7th character | One of the following 7th characters is to be assigned to codes in subcategory E09.35 to designate laterality of the disease: | One of the following 7th characters is to be assigned to codes in subcategory H35.31 to designate the stage of the disease: |
| Use additional code | code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5) code to identify control using: injectable non-insulin antidiabetic drugs (Z79.85) | — |
| Code first | poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4) | — |
Derived from the official CMS ICD-10-CM tabular data (FY2026). Not billing advice; verify sequencing rules for the encounter. All data sources